GlucoTrack, Inc. (GCTK)
| Market Cap | 708.51K -90.0% |
| Revenue (ttm) | n/a |
| Net Income | -15.95M |
| EPS | -112.77 |
| Shares Out | 798.14K |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 321,181 |
| Open | 1.1000 |
| Previous Close | 1.1100 |
| Day's Range | 0.8611 - 1.1000 |
| 52-Week Range | 0.86105 - 112.5000 |
| Beta | 0.73 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 12, 2026 |
About GCTK
GlucoTrack, Inc., a medical device company, focuses on the development of an implantable continuous blood glucose monitor (CBGM) for people with diabetes in the United States. The company develops the GlucoTrack CBGM, a long-term implantable blood-based CBGM for use by Type 1 diabetes patients and insulin-dependent Type 2 diabetes patients. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Rutherford, New Jersey.
Financial Performance
Financial StatementsNews
GlucoTrack subsidiary announces public launch of Qare
Lokahi Therapeutics, a subsidiary of Glucotrack (GCTK), announced the public launch of Qare. Launching initially in the GLP-1 category, Qare enables users to compare their self-reported results, side ...
GlucoTrack Registration statement: Registration filing
GlucoTrack filed a registration statement on October 14, 2026, providing details about a securities offering with the SEC.
GlucoTrack Proxy statement: Proxy filing
GlucoTrack filed a proxy statement on October 13, 2026, providing details for shareholder voting and corporate governance matters.
GlucoTrack prices 169,388 shares at $2.04 in public offering
Glucotrack (GCTK) announced the pricing of a “best efforts” public offering of 169,388 shares of common stock at a price of $2.04 per share and, in lieu of shares of…
Glucotrack, Inc. Announces Pricing of $3 Million Public Offering
RUTHERFORD, N.J. & LA JOLLA, Calif.--(BUSINESS WIRE)--Glucotrack, Inc. Announces Pricing of $3 Million Public Offering.
Lōkahi Therapeutics™ and Glucotrack CEO Erik Emerson Provides Strategic Update on LT-100, ai² Platform Growth and Clinical Development Priorities
RUTHERFORD, N.J. & LA JOLLA, Calif.--(BUSINESS WIRE)--Lōkahi CEO Erik Emerson outlines LT-100 progress, ai² platform growth, and a strategy to discover, advance, and monetize assets.
GlucoTrack Registration statement: Registration filing
GlucoTrack filed a registration statement on September 18, 2026, providing details about a securities offering with the SEC.
GlucoTrack files to sell 43.45M shares of common stock for holders
This filing relates to the offer and sale from time to time by the selling stockholders of up to 43.45M shares of common stock. The company is not selling any…
GlucoTrack Transcript: AGM 2026
The meeting approved two key proposals for stock issuance related to an ELOC agreement and bridge financing, both in compliance with NASDAQ rules. A quorum was present, and all proposals passed with the required votes. Final results will be filed with the SEC.
GlucoTrack announces $11.5M financing
Glucotrack (GCTK) announced definitive agreements for convertible notes with an aggregate principal amount of approximately $11.5M, including approximately $4.5M of new cash investment and approximate...
Glucotrack Announces $11.5 Million Financing
RUTHERFORD, N.J. & LA JOLLA, Calif.--(BUSINESS WIRE)-- #Glucotrack--Glucotrack announces $11.5M convertible note financing, including new capital and note rollover, to support strategic growth.
GlucoTrack announces collaboration with SDSU Fowler College of Business
Lundefinedkahi Therapeutics, a subsidiary of Glucotrack (GCTK), announced a collaboration with San Diego State University’s, or SDSU, Fowler College of Business, expanding the ai Futures Lab and stren...
GlucoTrack Inc trading halted, news pending
19:50 EDT GlucoTrack (GCTK) Inc trading halted, news pending
GlucoTrack announces 1-for-15 reverse stock split
Glucotrack (GCTK) announced that it will effect a 1-for-15 reverse stock split of its issued and outstanding common stock par value $0.001 per share, effective with the opening of trading…
Glucotrack, Inc. Announces Reverse Stock Split
RUTHERFORD, N.J. & LA JOLLA, Calif.--(BUSINESS WIRE)--Glucotrack (Nasdaq: GCTK) announced a 1-for-15 reverse stock split effective August 31, 2026, to support Nasdaq listing compliance.
GlucoTrack subsidiary initiates clinical trial manufacturing for LT-100
Lokahi Therapeutics, a subsidiary of Glucotrack (GCTK), announced that it has started its initial Good Manufacturing Practice, GMP, manufacturing campaign for LT-100, the Company’s lead development ca...
Lokahi expands ai2 Future Labs asset origination netowrk
Lokahi Therapeutics, a subsidiary of Glucotrack (GCTK), announced the continued participation of the University of Georgia’s Student Industry Fellows Program in the ai Futures Lab. The renewed collabo...
GlucoTrack Proxy statement: Proxy filing
GlucoTrack filed a proxy statement on August 21, 2026, providing details for shareholder voting and corporate governance matters.
GlucoTrack Transcript: AGM 2026
The meeting saw the election of six directors, approval of executive compensation, auditor ratification, amendments for potential reverse stock splits, and warrant inducement proposals. All items received the necessary votes and will be reported to the SEC.
GlucoTrack achieves key compliance milestone
Glucotrack (GCTK) announced that the Nasdaq Hearings Panel has granted the Company’s request for continued listing on The Nasdaq Stock Market, subject to certain conditions. The Panel has confirmed th...
Glucotrack Achieves Key Compliance Milestone and Advances Strategic Transformation
RUTHERFORD, N.J. & LA JOLLA, Calif.--(BUSINESS WIRE)--"We are approaching the months ahead with confidence, urgency, and a clear sense of purpose," said Erik Emerson, CEO of Glucotrack.
GlucoTrack Quarterly report: Q2 2026
GlucoTrack has published its Q2 2026 quarterly earnings report on August 14, 2026.
GlucoTrack Proxy statement: Proxy filing
GlucoTrack filed a proxy statement on August 10, 2026, providing details for shareholder voting and corporate governance matters.
E.F. Hutton & Co. Acts as Exclusive Financial Advisor for $5.5 Million Financing for Glucotrack
NEW YORK, Aug. 06, 2026 (GLOBE NEWSWIRE) -- E.F. Hutton & Co. (“E.F. Hutton”), a leading investment banking and financial advisory firm, today announced that it acted as exclusive financial advisor in...
GlucoTrack announces $5.5M financing
Glucotrack (GCTK) announced definitive agreements for approximately $5.5M in financing from participating institutional investors, including a $2M equity financing priced at $0.75 per unit and a $3.5M...